Efficacy and safety of calcitonin gene-related peptide monoclonal antibodies for cluster headache: a systematic review and frequentist-Bayesian meta-analysis
Abstract
Background: Calcitonin gene-related peptide (CGRP) monoclonal antibodies have transformed migraine prevention, but their efficacy in cluster headache remains uncertain.
Methods: We searched PubMed, Embase, Cochrane, Web of Science, and ClinicalTrials.gov through February 28, 2026, for trials of CGRP monoclonal antibodies in cluster headache. The primary outcome was weekly cluster headache attack frequency, quantified as mean difference (MD) with 95% confidence intervals. Bayesian meta-analysis with five prior specifications and trial sequential analysis were conducted as prespecified sensitivity analyses.
Results: Four trials (655 participants) were included. The pooled MD was - 0.81 attacks per week (95%CI - 2.24 to 0.62; P = 0.265; I2 = 8%). Neither episodic (MD - 1.21; 95%CI - 5.20 to 2.78) nor chronic (MD - 0.93; 95%CI - 2.89 to 1.03) subgroups reached significance (P = 0.90). The odds ratio for 50% or greater responder rate was 1.39 (95%CI 0.88-2.19; P = 0.159); risk ratios reached significance (1.25; 95%CI 1.04-1.49; P = 0.017), a discrepancy driven by high placebo rates (27-53%). Bayesian analysis showed an 81.1% posterior probability of any benefit, but only 17.9% probability that the true reduction reached 2 or more attacks per week. Trial sequential analysis indicated that for an assumed effect of 2.5 attacks per week, accrued information exceeded the required information size (135.6%) without the cumulative Z-statistic crossing the efficacy boundary; for an…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 655 participants or records.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.